Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 186

1.

Anticancer Activity of Apaziquone in Oral Cancer Cells and Xenograft Model: Implications for Oral Cancer Therapy.

Srivastava G, Somasundaram RT, Walfish PG, Ralhan R.

PLoS One. 2015 Jul 24;10(7):e0133735. doi: 10.1371/journal.pone.0133735. eCollection 2015.

2.

Anticancer activity of pyrithione zinc in oral cancer cells identified in small molecule screens and xenograft model: Implications for oral cancer therapy.

Srivastava G, Matta A, Fu G, Somasundaram RT, Datti A, Walfish PG, Ralhan R.

Mol Oncol. 2015 May 21. pii: S1574-7891(15)00120-9. doi: 10.1016/j.molonc.2015.05.005. [Epub ahead of print]

PMID:
26115765
3.

Prediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancer.

Chauhan SS, Kaur J, Kumar M, Matta A, Srivastava G, Alyass A, Assi J, Leong I, MacMillan C, Witterick I, Colgan TJ, Shukla NK, Thakar A, Sharma MC, Siu KW, Walfish PG, Ralhan R.

Oncogenesis. 2015 Apr 20;4:e147. doi: 10.1038/oncsis.2015.7.

4.
5.

Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies.

Orlov S, Salari F, Kashat L, Walfish PG.

J Clin Endocrinol Metab. 2015 May;100(5):1738-41. doi: 10.1210/jc.2014-4560. Epub 2015 Mar 9.

PMID:
25751110
6.

Nuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomas.

Assi J, Srivastava G, Matta A, MacMillan C, Ralhan R, Walfish PG.

PLoS One. 2015 Feb 19;10(2):e0107586. doi: 10.1371/journal.pone.0107586. eCollection 2015.

7.

Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients.

Kumar M, Srivastava G, Kaur J, Assi J, Alyass A, Leong I, MacMillan C, Witterick I, Shukla NK, Thakar A, Duggal R, Roychoudhury A, Sharma MC, Walfish PG, Chauhan SS, Ralhan R.

J Transl Med. 2015 Jan 16;13:8. doi: 10.1186/s12967-014-0369-9.

8.

Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients.

Srivastava G, Assi J, Kashat L, Matta A, Chang M, Walfish PG, Ralhan R.

BMC Cancer. 2014 Sep 29;14:726. doi: 10.1186/1471-2407-14-726.

9.

Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis.

Hasan R, Sharma R, Saraya A, Chattopadhyay TK, DattaGupta S, Walfish PG, Chauhan SS, Ralhan R.

BMC Cancer. 2014 Jan 2;14:2. doi: 10.1186/1471-2407-14-2.

10.

Slug is a predictor of poor prognosis in esophageal squamous cell carcinoma patients.

Hasan MR, Sharma R, Saraya A, Chattopadhyay TK, DattaGupta S, Walfish PG, Chauhan SS, Ralhan R.

PLoS One. 2013 Dec 18;8(12):e82846. doi: 10.1371/journal.pone.0082846. eCollection 2013.

11.

The adenovirus 55 residue E1A protein is a transcriptional activator and binds the unliganded thyroid hormone receptor.

Arulsundaram VD, Webb P, Yousef AF, Pelka P, Fonseca GJ, Baxter JD, Walfish PG, Mymryk JS.

J Gen Virol. 2014 Jan;95(Pt 1):142-52. doi: 10.1099/vir.0.056838-0. Epub 2013 Oct 17.

12.

S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia.

Kaur J, Matta A, Kak I, Srivastava G, Assi J, Leong I, Witterick I, Colgan TJ, Macmillan C, Siu KW, Walfish PG, Ralhan R.

Int J Cancer. 2014 Mar 15;134(6):1379-88. doi: 10.1002/ijc.28473. Epub 2013 Oct 8.

PMID:
24122701
13.

Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence.

Assi J, Srivastava G, Matta A, Chang MC, Walfish PG, Ralhan R.

PLoS One. 2013 Sep 13;8(9):e74437. doi: 10.1371/journal.pone.0074437. eCollection 2013.

14.

Clinical significance of altered expression of β-catenin and E-cadherin in oral dysplasia and cancer: potential link with ALCAM expression.

Kaur J, Sawhney M, DattaGupta S, Shukla NK, Srivastava A, Walfish PG, Ralhan R.

PLoS One. 2013 Jun 28;8(6):e67361. doi: 10.1371/journal.pone.0067361. Print 2013.

15.

Secretome proteins as candidate biomarkers for aggressive thyroid carcinomas.

Chaker S, Kashat L, Voisin S, Kaur J, Kak I, MacMillan C, Ozcelik H, Siu KW, Ralhan R, Walfish PG.

Proteomics. 2013 Mar;13(5):771-87. doi: 10.1002/pmic.201200356.

PMID:
23319340
16.

Iodine nutrition during pregnancy in Toronto, Canada.

Katz PM, Leung AM, Braverman LE, Pearce EN, Tomlinson G, He X, Vertes J, Okun N, Walfish PG, Feig DS.

Endocr Pract. 2013 Mar-Apr;19(2):206-11. doi: 10.4158/EP12193.OR.

17.

Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma.

Kunavisarut T, Kak I, Macmillan C, Ralhan R, Walfish PG.

BMC Cancer. 2012 Nov 15;12:523. doi: 10.1186/1471-2407-12-523.

18.

Activated leukocyte cell adhesion molecule is a marker for thyroid carcinoma aggressiveness and disease-free survival.

Chaker S, Kak I, MacMillan C, Ralhan R, Walfish PG.

Thyroid. 2013 Feb;23(2):201-8. doi: 10.1089/thy.2012.0405.

PMID:
23148625
19.

An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.

He HC, Kashat L, Kak I, Kunavisarut T, Gundelach R, Kim D, So AK, MacMillan C, Freeman JL, Ralhan R, Walfish PG.

PLoS One. 2012;7(9):e42893. doi: 10.1371/journal.pone.0042893. Epub 2012 Sep 25.

20.

Biotinidase is a novel marker for papillary thyroid cancer aggressiveness.

So AK, Kaur J, Kak I, Assi J, MacMillan C, Ralhan R, Walfish PG.

PLoS One. 2012;7(7):e40956. doi: 10.1371/journal.pone.0040956. Epub 2012 Jul 23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk